| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine, particularly to the addiction pharmacology, and concerns new application of threonyl-lysyl-prolyl-arginyl-prolyl-glycyl-prolyl-diacetate (Selank) as an agent for managing alcohol abstinence syndrome (AAC). It has been stated that Selank eliminates anxiety induced by withdrawal of ethanol. Selank has been detected to recover a threshold of tactile sensation reduced in the period of alcohol withdrawal to the level observed in intact animals.EFFECT: anxiolytic Selank can be applied as the effective agent for correction of clinical manifestations of mild and moderate alcohol abstinence syndrome with no adverse side effects.7 dwg, 1 tbl, 3 ex |
